Cargando…

Neurological Immunotoxicity from Cancer Treatment

The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wesley, Sarah F., Haggiagi, Aya, Thakur, Kiran T., De Jager, Philip L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268562/
https://www.ncbi.nlm.nih.gov/pubmed/34201529
http://dx.doi.org/10.3390/ijms22136716
_version_ 1783720384659456000
author Wesley, Sarah F.
Haggiagi, Aya
Thakur, Kiran T.
De Jager, Philip L.
author_facet Wesley, Sarah F.
Haggiagi, Aya
Thakur, Kiran T.
De Jager, Philip L.
author_sort Wesley, Sarah F.
collection PubMed
description The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In particular, this review details the neurological irAEs from immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell immunotherapies. The recognition and treatment of neurological irAEs has variable success, depending on the severity and nature of the neurological involvement. Understanding the involved mechanisms, predicting those at higher risk for irAEs, and establishing safety parameters for resuming cancer immunotherapies after irAEs are all important fields of ongoing research.
format Online
Article
Text
id pubmed-8268562
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82685622021-07-10 Neurological Immunotoxicity from Cancer Treatment Wesley, Sarah F. Haggiagi, Aya Thakur, Kiran T. De Jager, Philip L. Int J Mol Sci Review The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In particular, this review details the neurological irAEs from immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell immunotherapies. The recognition and treatment of neurological irAEs has variable success, depending on the severity and nature of the neurological involvement. Understanding the involved mechanisms, predicting those at higher risk for irAEs, and establishing safety parameters for resuming cancer immunotherapies after irAEs are all important fields of ongoing research. MDPI 2021-06-23 /pmc/articles/PMC8268562/ /pubmed/34201529 http://dx.doi.org/10.3390/ijms22136716 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wesley, Sarah F.
Haggiagi, Aya
Thakur, Kiran T.
De Jager, Philip L.
Neurological Immunotoxicity from Cancer Treatment
title Neurological Immunotoxicity from Cancer Treatment
title_full Neurological Immunotoxicity from Cancer Treatment
title_fullStr Neurological Immunotoxicity from Cancer Treatment
title_full_unstemmed Neurological Immunotoxicity from Cancer Treatment
title_short Neurological Immunotoxicity from Cancer Treatment
title_sort neurological immunotoxicity from cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268562/
https://www.ncbi.nlm.nih.gov/pubmed/34201529
http://dx.doi.org/10.3390/ijms22136716
work_keys_str_mv AT wesleysarahf neurologicalimmunotoxicityfromcancertreatment
AT haggiagiaya neurologicalimmunotoxicityfromcancertreatment
AT thakurkirant neurologicalimmunotoxicityfromcancertreatment
AT dejagerphilipl neurologicalimmunotoxicityfromcancertreatment